Reference
Gorsi HS, et al. Single-agent bevacizumab in the treatment of recurrent or refractory pediatric low-grade glioma: A single institutional experience. Pediatric Blood and Cancer 65: e27234, No. 9, Sep 2018. Available from: URL: http://doi.org/10.1002/pbc.27234 - USA
Rights and permissions
About this article
Cite this article
Bevacizumab. Reactions Weekly 1718, 52 (2018). https://doi.org/10.1007/s40278-018-51396-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-018-51396-7